IN2014CN04401A - - Google Patents

Info

Publication number: IN2014CN04401A
Authority: IN; India
Prior art keywords: compounds; treatment; glp; obesity; mediate
Prior art date: 2011-12-23

Application number

Other languages

English (en)

Inventor

Dieter Wolfgang Hamprecht

Jakob Lind Tolborg

Ditte Riber

Original Assignee

Zealand Pharma As

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-23

Filing date

2012-12-19

Publication date

2015-09-04

2012-12-19 Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As

2015-09-04 Publication of IN2014CN04401A publication Critical patent/IN2014CN04401A/en

Links

150000001875 compounds Chemical class 0.000 abstract 2
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
101500028775 Homo sapiens Glucagon Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
230000004584 weight gain Effects 0.000 abstract 1
235000019786 weight gain Nutrition 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Zoology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IN4401CHN2014 2011-12-23 2012-12-19 IN2014CN04401A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161579888P	2011-12-23	2011-12-23
PCT/EP2012/076137 WO2013092703A2 (en)	2011-12-23	2012-12-19	Glucagon analogues

Publications (1)

Publication Number	Publication Date
IN2014CN04401A true IN2014CN04401A (es)	2015-09-04

Family

ID=47594620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN4401CHN2014 IN2014CN04401A (es)	2011-12-23	2012-12-19

Country Status (20)

Country	Link
US (2)	US20130316941A1 (es)
EP (1)	EP2793931A2 (es)
JP (1)	JP2015502380A (es)
KR (1)	KR20140114845A (es)
CN (1)	CN104144696A (es)
AP (2)	AP2014007797A0 (es)
AU (1)	AU2012357739A1 (es)
BR (1)	BR112014015681A2 (es)
CA (1)	CA2858949A1 (es)
EA (1)	EA201490982A1 (es)
HK (1)	HK1200369A1 (es)
IL (1)	IL232800A0 (es)
IN (1)	IN2014CN04401A (es)
MA (1)	MA35864B1 (es)
MX (1)	MX2014007120A (es)
PE (1)	PE20142113A1 (es)
PH (1)	PH12014501336A1 (es)
SG (1)	SG11201403377QA (es)
TN (1)	TN2014000224A1 (es)
WO (1)	WO2013092703A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2454282E (pt)	2009-07-13	2015-06-23	Zealand Pharma As	Análogos de glucagão acilados
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
US9169310B2 (en)	2010-06-24	2015-10-27	Zealand Pharma A/S	Glucagon analogues
JP6228187B2 (ja)	2012-05-03	2017-11-08	ジーランドファーマアクティーゼルスカブ	Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
EP2664374A1 (en) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
JP6534927B2 (ja)	2012-07-23	2019-06-26	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt)	2012-12-21	2018-02-12	Sanofi	Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
GB201315335D0 (en) *	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
PE20160683A1 (es)	2013-10-17	2016-07-21	Zealand Pharma As	Analogos de glucagon acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
MX2016005556A (es)	2013-11-06	2016-07-15	Zealand Pharma As	Compuestos agonistas duales de gip-glp-1 y procedimientos.
US10131702B2 (en)	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
ES2883345T3 (es)	2014-10-29	2021-12-07	Zealand Pharma As	Compuestos agonistas del GIP y métodos
AR103242A1 (es) *	2015-01-09	2017-04-26	Lilly Co Eli	Compuestos co-agonistas de gip y glp-1
US10213487B2 (en)	2015-02-17	2019-02-26	Eli Lilly And Company	Nasal powder formulation for treatment of hypoglycemia
CA2979950A1 (en)	2015-03-18	2016-09-22	Zealand Pharma A/S	Amylin analogues
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
AU2016247499B2 (en)	2015-04-16	2020-09-03	Zealand Pharma A/S	Acylated glucagon analogue
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) *	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
GB2566228A (en)	2016-06-09	2019-03-06	AmideBio LLC	Glucagon analogs and methods of use thereof
MA45843B1 (fr)	2016-08-05	2021-06-30	Boehringer Ingelheim Int	Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
BR112019010624A2 (pt) *	2016-12-09	2019-10-22	Zealand Pharma As	agonistas duplos de glp-1/glp-2 acilados e composição
HRP20240371T1 (hr) *	2017-08-16	2024-06-07	Dong-A St Co., Ltd	Peptidni analog aciliranog oksintomodulina
EA202091804A1 (ru)	2018-02-02	2020-12-24	Бёрингер Ингельхайм Интернациональ Гмбх	Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
EP3746443B1 (en)	2018-02-02	2022-07-06	Boehringer Ingelheim International GmbH	Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3746449B1 (en)	2018-02-02	2022-03-30	Boehringer Ingelheim International GmbH	Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149657A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
CN111349155B (zh) *	2018-12-24	2022-04-05	浙江和泽医药科技股份有限公司	一种胰高血糖素类似物及其制备方法和用途
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
GB201908424D0 (en)	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
CN114641303A (zh)	2019-11-11	2022-06-17	勃林格殷格翰国际有限公司	Npy2受体激动剂
HUE069479T2 (hu)	2020-05-22	2025-04-28	Boehringer Ingelheim Int	Alkil 7-amino-5-metil-[1,2,5]-oxadiazolo[3,4-b]piridin-karboxilát folyamatos elõállítási eljárása
EP4153599B1 (en)	2020-05-22	2024-03-13	Boehringer Ingelheim International GmbH	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113292646B (zh) *	2020-05-29	2022-05-13	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
CR20230074A (es)	2020-08-07	2023-04-19	Boehringer Ingelheim Int	Agonistas del receptor npy2 solubles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU723268B2 (en)	1996-09-09	2000-08-24	Zealand Pharma A/S	Improved solid-phase peptide synthesis and agent for use in such synthesis
WO1999046283A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
KR101349808B1 (ko)	2005-06-13	2014-02-13	임페리얼 이노베이션스 리미티드	섭취행동에 관한 신규 화합물들 및 이들의 효능
AU2007221366B2 (en)	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
USRE47123E1 (en)	2006-07-18	2018-11-13	Sanofi	EPHA2 receptor antagonist antibodies
KR20150116465A (ko)	2007-02-15	2015-10-15	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/ｇｌｐ-1 수용체 공동-항진물질
ATE520714T1 (de)	2007-06-15	2011-09-15	Zealand Pharma As	Glucagonanaloga
US8546327B2 (en)	2008-06-17	2013-10-01	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja)	2008-06-17	2015-07-22	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
CA2747197A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
PT2454282E (pt) *	2009-07-13	2015-06-23	Zealand Pharma As	Análogos de glucagão acilados
EP2525809B1 (en) *	2010-01-20	2016-08-03	Zealand Pharma A/S	Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions
UY33462A (es) *	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon

2012
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/xx unknown
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/ko not_active Withdrawn
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/zh active Pending
- 2012-12-19 EA EA201490982A patent/EA201490982A1/ru unknown
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/pt not_active IP Right Cessation
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/ja active Pending
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/es unknown
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/es not_active Application Discontinuation
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/xx unknown
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/xx unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/fr unknown
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AP2014007774A0 (en)	2014-07-31
US20130316941A1 (en)	2013-11-28
TN2014000224A1 (en)	2015-09-30
PH12014501336A1 (en)	2014-09-15
WO2013092703A2 (en)	2013-06-27
AU2012357739A1 (en)	2014-07-03
KR20140114845A (ko)	2014-09-29
BR112014015681A2 (pt)	2019-09-24
AP2014007797A0 (en)	2014-07-31
CN104144696A (zh)	2014-11-12
EP2793931A2 (en)	2014-10-29
JP2015502380A (ja)	2015-01-22
MX2014007120A (es)	2015-03-05
WO2013092703A3 (en)	2013-11-14
PE20142113A1 (es)	2014-12-03
HK1200369A1 (en)	2015-10-09
SG11201403377QA (en)	2014-07-30
IL232800A0 (en)	2014-07-31
EA201490982A1 (ru)	2015-01-30
US20160347813A1 (en)	2016-12-01
CA2858949A1 (en)	2013-06-27
MA35864B1 (fr)	2014-12-01

Publication	Publication Date	Title
IN2014CN04401A (es)	2015-09-04
PH12015500531A1 (en)	2015-05-11	Glucagon analogues
MX2016004907A (es)	2016-09-28	Analogos del glucagon.
MY188182A (en)	2021-11-24	Acylated glucagon analogues
PH12016500675B1 (en)	2016-05-30	Acylated glucagon analogues
TN2012000560A1 (en)	2014-04-01	Glucagon analogues
MY160219A (en)	2017-02-28	Glucagon analogues
TN2012000567A1 (en)	2014-04-01	Glucagon analogues
MX2011006315A (es)	2011-09-22	Analogos de glucagon.
MX2011006320A (es)	2011-09-22	Analogos de glucagon.
MX2011006314A (es)	2011-09-22	Analogos de glucagon.
MX2017012864A (es)	2018-06-12	Analogo acilado del glucagon.
MX2016013244A (es)	2017-01-16	Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016013243A (es)	2017-02-23	Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2014015423A (es)	2015-04-09	Analogos de peptido de exedina-4.
HK1214829A1 (zh)	2016-08-05	治疗肽
TN2011000667A1 (en)	2013-05-24	Acylated glucagon analogues